Ronald E. Blaylock, a director at Pfizer (PFE), filed a Form 4 showing he acquired 39,231 shares on August 5, 2026. The transaction was valued at $998,821.26, with shares purchased at $25.46 each.
This filing was part of a cluster, as two insiders reported buying PFE shares on the same day. The combined notional value of insider purchases reported for the ticker reached $1,959,189.90. Such coordinated activity from multiple insiders may be interpreted by some market participants as a sign of alignment with shareholders.